Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +47.88%
#2 Pons Pons +38.42%
#3 PondCoin PondCoin +38.08%
#4 Purr Purr +30.23%
#5 TENDIES TENDIES +30.09%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.85%
#7 Magma Finance Magma Finance +27.70%
#8 Starpower Starpower +26.83%
#9 StonkBroker StonkBroker +26.40%
#10 SkyAI SkyAI +24.68%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
설정
언어
한국어
통화
USD
테마
Celularity Inc. Celularity Inc.

Celularity Inc.

CELU
주식 순위 #29003
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to... Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
주가
$0.81
시가총액
$23.45M
변동 (1일)
9.95%
변동 (1년)
-77.56%
국가
US
거래 Celularity Inc. (CELU)

카테고리

Healthcare
Celularity Inc. (CELU)의 EPS
2026 기준 EPS TTM: 0
Celularity Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Celularity Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH